Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-06-26
2007-06-26
Rawlings, Stephen L. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S069100, C530S387300
Reexamination Certificate
active
10243130
ABSTRACT:
Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. The invention also provides methods for increasing the affinity of monoclonal antibodies and monoclonal antibodies with increased affinity.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5885827 (1999-03-01), Wabl et al.
patent: 5907079 (1999-05-01), Mak et al.
patent: 6146894 (2000-11-01), Nicolaides et al.
patent: 6191268 (2001-02-01), Liskay et al.
patent: 6287862 (2001-09-01), delCardayre et al.
patent: 6808894 (2004-10-01), Nicolaides et al.
patent: 2003/0143682 (2003-07-01), Nicolaides et al.
patent: 2240609 (1999-10-01), None
patent: WO 97/05268 (1997-02-01), None
patent: 99/19492 (1999-04-01), None
patent: WO 02/37967 (2002-05-01), None
patent: WO 02/054856 (2002-07-01), None
patent: WO2005/011735 (2005-02-01), None
Giusti et al. (Proc. Natl. Acad. Sci. USA. May 1987; 84 (9): 2926-2930).
Chien et al. (Proc. Natl. Acad. Sci. USA. Jul. 1989; 86 (14): 5532-5536).
Caldas et al. (Mol. Immunol. May 2003; 39 (15): 941-952).
Tan et al. (Biophys. J. Sep. 1998; 75: 1473-1482).
Kipriyanov et al. (Protein Eng. Apr. 1997; 10 (4): 445-453).
Xiang et al. (J. Mol. Biol. 1995; 253: 385-390).
Xiang et al. (Protein Eng. 1999; 12 (5): 417-421).
Jung et al. (J. Mol. Biol. 2001; 309: 701-716).
Low, N.M. et al., “Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,”J Mol Biol(1996) 260:359-368.
Coia, G. et al., “Protein affinity maturation in vivo usingE. colimutator cells,”J Immunol Methods(2001) 251:187-193.
Wabl, M. et al., “Hypermutation in antibody affinity maturation,”Curr Opin Immunol(1999) 11:186-189.
Li, Y. et al., “Three-Dimensional Structures of the Free and Antigen-Bound Fab from Monoclonal Antilysozyme Antibody HyHEL-63,”Biochemistry(2000) 39:6296-6309.
Irving, R.A., “Affinity maturation of recombinant antibodies usingE. colimutator cells,”Immunotechnology 2, 1996, 127-143.
Wiesendanger, M., et al., “Somatic hypermutation, transcription, and DNA mismatch repair,”Cell, 1998, 94, 415-418.
Reynaud, C.-A., et al., “Mismatch repair and immunoglobulin gene hypermutation: did we learn something?,”Immunology Today, 1999, 20(11), 522-527.
Allen, D., et al., “MutS mediates heteroduplex loop formation by a translocation mechanism,”EMBO J., 1997, 16(14), 4467-4476.
Baker, S.M., et al., “Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis,”Cell, 1995, 82, 309-319.
Bell, C.J., et al., “Assignment of 30 microsatellite loci to the linkage map ofarabidopsis,” Enomics, 1994, 19, 137-144.
Bignami M., “Unmaking a Killer: DNAO6-methylguanine and the Cytotoxicity of Methylating Agents”,Mutat. Res., 2000, 462, 71-82.
Bjornson, K., et al., “Moduation of MutS ATP hydrolysis by DNA cofactors,”Biochemistry, 2000, 39, 3176-3183.
Bronner C.E., et al., “Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer,”Nature, 1994, 368, 258-261.
de Wind, N., et al., “Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer,”Cell, 1995, 82, 321-330.
Drummond, J.T., et al., “Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells,”Science, 1995, 268, 1909-1912.
Drummond, J.T., et al., “Cisplatin and adriamycin resistence are associated with mutlα and mismatch repair deficiency in an ovarian tumor cell line,”J. Biological Chemistry, 1996, 271(33), 19645-19648.
Edelmann, W., et al., “Meiotic pachytene arrest in MLH1-deficient mice,”Cell, 1996, 85, 1125-1134.
Emery, S.C. and Harris, W.J., “Strategies for Humanizing Antibodies” In C.A.K. Borrebaeck (Ed.), Antibody Engineering. Oxford University Press, N.Y. 1995; pp. 159-183.
Eshleman, J.R., et al., “Mismatch repair defects in human carcinogenesis,”Human Molecular Genetics, 1996, 5, 1489-1494.
Fiedler, U. et al., “High-Level Production and Long-Term Storage of Engineered Antibodies in Transgenic Tobacco Seeds”,Bio/Technology, 1995, 13, 1090-1093.
Frigerio, L. et al., “Assembly, Secretion, and Vacuolar Delivery of a Hybrid Immunoglobin in Plants”,Plant Physiol, 2000, 123, 1483-1494.
Galio, L., et al., “ATP hydrolysis-dependent formation of a dynamic ternary nucleoprotein complex with MutS and MutL,”Nucleic Acids Research, 1999, 27(11), 2325-2331.
Glaser, V., “Gene Therapy's Other Investment Window”,Nat. Biotechnol., 1996, 14, 1216-1217.
Harfe, B.D., “DNA mismatch repair and genetic instability,”Annu. Rev. Genet., 2000, 34, 359-399.
Hoang J., et al., “BAT-26, an Indicator of the Replication Error Phenotype in Colorectal Cancers and Cell Lines”,Cancer Res., 1997, 57, 300-303.
Honma, M. et al., “Cytotoxic and Mutagenic Responses to X-rays and Chemical Mutagens in Normal and p53-mutated Human Lymphoblastoid Cells”,Mut. Res., 1997, 347, 89-98.
Jiricny, J., et al., “Mismatch repair defects in cancer,”Curr. Opin. Genet. Dev., 2000, 10, 157-161.
Karran, P., et al., “Genomic instability and tolerance to alkylating agents,”Cancer Surveys, 1996, 28, 69-71.
Khazaeli, M.B. et al., “Human Immune Response to Monoclonal Antibodies”,J. Immunother., 1994, 15, 42-52.
Kong, Q., et al., “PMS2-deficiency diminishes hypermutation of a lamdal transgene in young but not older mice”,Mol. Immunol., 1999, 36, 83-91.
Leach, F.S., et al., “Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer,”Cell, 1993, 75, 1215-1225.
Liu, T., et al., “Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer,”Genes, Chromosomes&Cancer, 2000, 27, 17-25.
McCallum, C.M., “Targeted screening for induced mutations,”Nature Biotechnology, 2000, 18, 455-457.
Modrich, P., “Mismatch repair, genetic stability, and cancer,”Science, 1994, 266, 1959-1960.
Neuberger, M., et al., “Mice perform a human repertoire,”Nature, 1997, 386, 25-26.
Nicolaides, N.C., et al., “The jun family members, c-jun and junD, transactivate the human c-myb, promotor via an Ap1-like element,”J. Biological Chemistry, 1992, 267(27), 19665-19672.
Nicolaides, N.C., et al., “Genomic organization of the humanPMS2gene family,”Genomics, 1995, 30, 195-206.
Nicolaides, N.C., et al., “Positive autoregulation of c-myb, expression via Myb binding sites in the 5' flanking region of the human c-mybgene,”Moecular and Cellular Biology, 1991, 11(12), 6166-6176.
Nicolaides, N.C., “A naturally occuringhPMS2mutation can confer a dominant negative nutator phenotype,”Mol. Cell. Biol., 1998, 18(3), 1635-1641.
Nicolaides, N.C., et al., “Analysis of the 5' region ofPMS2reveals heterogeneous transcripts and a novel overlapping gene,”Genomics, 1995, 29, 329-334.
Nicolaides, N.C., et al., “Mutations of two PMS homologues in hereditary nonpolyposis colon cancer,”Nature, 1994, 371, 75-80.
Palombo, F., et al., “Mismatch repair and cancer,”Nature, 1994, 367, 417.
Papadopoulos, N.,
Grasso Luigi
Nicolaides Nicholas C.
Sass Philip M.
Morphotek Inc.
Rawlings Stephen L.
Woodcock & Washburn LLP
LandOfFree
Antibodies and methods for generating genetically altered... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies and methods for generating genetically altered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies and methods for generating genetically altered... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3822499